Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 2013 Annual Outsourcing Survey | Contract Pharma

What are you searching for?

Sign in
Outsourcing Survey

2013 Annual Outsourcing Survey

Welcome to our 9th Annual Contract Pharma Outsourcing Survey! More than 200 sponsor-side respondents offered up their opinions on outsourcing trends for this year's poll.

By: Gil Roth

President, Pharma & Biopharma Outsourcing Association

Here’s a breakdown of the respondents, by company type and job function:

Company Type
  • Small/Mid-Tier Pharma: 20.1%
  • Top 20 Pharma: 19.0%
  • Generic Pharma: 12.3%
  • Specialty Pharma: 12.3%
  • Emerging Biopharma: 8.4%
  • Virtual Pharma: 6.5%
  • Consumer/OTC: 5.2%
  • Top 10 Biopharma: 3.9%
  • Other: 12.3%

Job Function
  • Corporate Management: 21.4%
  • R&D: 20.4%
  • Project Manager: 8.4%
  • Purchasing/Sourcing: 8.4%
  • Production/Manufacturing/Packaging: 7.8%
  • QA/QC/Validation: 6.5%
  • Business Development: 5.2%
  • Contract Manager: 5.2%
  • Marketing/Sales: 4.5%
  • Clinical Research: 3.2%
  • Supply Chain Manager: 2.6%
  • Regulatory Affairs: 1.9%
  • Engineering: 1.3%
  • Other: 3.2%

Peaking?

Last year, 48% of respondents believed that they will spend the same or less on outsourcing spending in the coming year; this year, that climbed to 53%. Meanwhile, 49%, told us that they spent the same or less on outsourcing in the previous year, the same as in our 2012 survey. 18% of respondents said that 2012 saw no change in outsourcing spending from 2011.

28% of respondents tell us they had cancelled outsourcing projects in the previous year due to the economy; up from 23% in our 2012 survey. Small/Mid-Tier Pharma respondents had the highest “cancellation rate” of any company type, at 59% (!).

50% of respondents said that more than half of their outsourcing dollars go to preferred providers. 74% of Corporate Management respondents said the same but most other job categories cited lower figures (43% of R&D staff, and 20% QA/QC/Validation staff cited that large a figure).

46% of the respondents said that their companies outsource generic manufacturing, but only 52% of that group said they they have ascertained that their dosage form manufacturers and API suppliers have registered with FDA under GDUFA.

Download the 52-page survey today to find out about the latest pharma & biopharma outsourcing trends!
 
 
 

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics